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This study has investigated the ability of the vasoconstrictor peptide angiotensin II to activate human peripheral blood monocytes. Activation was 
monitored by measuring both the release of tumor necrosis factor a from monocytes and their adhesion to monolayers of human endothelial cells. 
Angiotensin II-elicited activation of monocytes was dose-dependent (half-maximally effective concentration =0.2 nM), saturable (maximally effective 
concentration =5 nM), and sensitive to inhibition by the angiotensin type 1 receptor antagonist ZD 7155. Such direct actions imply that angiotensin 
II is an important candidate stimulus for the subendothelial infiltration of monocytes observed in atherogenesis and hypertension. 
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1. Introduction 
Endothelial dysfunction and/or injury is one of the 
earliest events postulated to occur in the genesis of the 
atherosclerotic lesion [l]. This is followed by a series of 
events which include monocyte recruitment and macro- 
phage formation, transendothelial migration of mon- 
ocytes macrophages, lipid deposition, vascular smooth 
muscle cell proliferation and synthesis of extracellular 
matrix [ 11. Subendothelial monocyte/macrophage inva- 
sion of the vessel wall requires activation of peripheral 
blood monocytes and their specific interaction with the 
endothelial cell surface [2]. Thus, atherosclerotic lesions 
occur mainly in regions of blood vessels where rheologic 
conditions are optimal (i.e. low circulatory shear stress) 
for endothelium-monocyte contact and monocyte trans- 
migration [5]. The endothelial dysfunction and monocyte 
macrophage infiltration that occurs both in hypertension 
and with aging also occur preferentially in vessel loca- 
tions exposed to slow shear forces [3,4]. In the aorta and 
carotid artery of spontaneously hypertensive rats both 
subendothelial infiltration of mononuclear cells and en- 
dothelial dysfunction can be decreased by treatment of 
animals with angiotensin converting enzyme inhibitors 
(ACEI) [6]. These concomitant beneficial effects of ACE1 
have been proposed to result from either a primary ac- 
tion of ACE1 on endothelial function (e.g. via decreased 
bradykinin degradation and increased EDRF release) 
with secondary prevention of monocytelmacrophage in- 
filtration, or vice versa [6]. Other than blood pressure 
lowering effects, the mechanisms underlying primary ac- 
tions of ACE1 on monocyte/macrophage infiltration are 
unclear. To explore the possibility that angiotensin II 
(Ang II) might be directly involved in the process of 
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monocyte recruitment, we have investigated whether 
Ang II receptors are expressed by human peripheral 
blood monocytes and whether Ang II is capable of pro- 
moting monocyte activation and adhesion. 
2. Experimental 
2.1. Isolation and activation of peripheral blood monocytes and tumor 
necrosb factor (TNF) a measurements 
All solutions and chemicals used in isolation and activation proce- 
dures were endotoxin-free (endotoxin c 0.01 &ml). Human peripheral 
blood monocytes were isolated using the continuous Percoll gradient 
procedure xactly as described by Gmelig-Meyling and Waldmann [7l. 
Cells were finally resuspended and maintained in RPM1 1640 medium 
supplemented with 5% human AB serum, 15 &ml gentamycin and 10 
&ml polymyxin B, and 10 mM each of sodium pyruvate, non-essential 
amino acids, sodium bicarbonate and HEPES @H 7.4). The relative 
amount of monocytes and lymphocytes was determined using the 
Diffquick staining procedure (Merz and Dade). Monocyte suspensions 
were transferred into serum-free (5% human serum albumin instead of 
5% human AB serum) supplemented medium (cell count adjusted to 
5 x lo5 cells/ml) at least 2 h before all experimental protocols. Mon- 
ocyte activation by endotoxin (bacterial ipopolysaccharide (LPS)) or 
Ang II was determined by measuring the release of TNFa into the 
culture supematant (BIA assay, threshold sensitivity 0.05 ng TNFa; 
anti-TNFa antibodies provided by Hoffmann LaRoche Ltd., Basel, 
Switzerland). 
2.2. RNA isolation, RT-PCR, Southern analyses and probes 
Isolation of total RNA was performed according to Chomcxynski [8], 
and preparations were treated with RNase-free DNase. Reverse tran- 
scriptase reactions were performed according to standard procedures 
using AMV reverse transcriptase (Boehringer, Mannheim, Germany) 
and 2 pg of total RNA. Single-stranded cDNA corresponding to 200 
ng of total RNA was used in each PCR reaction. For PCR, Perkin 
Elmer machinery and reagents were used according to the suppliers 
protocols. The oligonucleotides used correlated to regions adjacent o 
the entire coding region of the human angiotensin AT, type receptor: 
antisense TTATTGATTCACTCTTCTAC; sense CGAACATGTCA- 
CTCAACCTC. Primers and conditions for cycling were selected using 
the Oligo program for Macintosh. 30 cycles with the following parame- 
ters were performed: 1 min each denaturation at 97”C, annealing at 
55°C and synthesis at 72°C. The identity of the amplificates generated 
was verified by partial sequencing and/or Southern blotting using a 
homologous partial, nested cDNA probe according to standard proto- 
cols. 
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2.3. Adhesion of monocytes to enabthelial cell monolayers 
Human umbilical vein endothelial cells (HUVEC; ATCC CRL 1730) 
were grown and maintained in supplemented RPM1 1640 medium (as 
above but with 10% human AB serum)under endotoxin-free condi- 
tions. Confluent cultures of HUVEC were changed to serum-free me- 
dium conditions (10% human AB serum replaced by 5% human serum 
albumin) at least 2 h before adhesion experiments. Monocytes (in 
serum-free supplemented medium) were activated by exposure for 6 h 
to either LPS or Ang II (10-s M). In some experiments monocytes were 
preincubated for 30 min with the AT, receptor antagonist ZD 7155 
(lo-* M) before exposure to Ang II. Monocytes continuously main- 
tained in serum-free supplemented medium served as negative controls. 
Following activation protocols, monocytes were washed once in semm- 
free medium and then seeded (at 5 x 10’ cells/well and into triplicate 
wells for each experimental point) onto confluent HUVEC monolayers. 
After 2 h, non-adherent monocytes were collected and counted. Mon- 
ocyte adhesion is given as the number of adherent cells expressed as the 
percent of that number initially seeded (100%). 
3. Results 
Total RNA from human peripheral blood monocytes 
and human vascular smooth muscle cells (as positive 
control) was subjected to RT-PCR using oligonucleo- 
tides specific for the human angiotensin type 1 (AT,) 
receptor. Both monocytes and smooth muscle cells ex- 
pressed ATi-specific transcripts (Fig. 1). The result was 
Southern blot 
Fig. 1. Expression of angiotensin AT, receptor transcripts in human 
monocytes and vascular smooth muscle cells. RT-PCR and Southern 
blot of amplificates of total RNA from peripheral blood monocytes 
(lane 2), cultured aortic smooth muscle cells (lane 1; positive control) 
and CHO cells (lane 3; negative control). M = DNA molecular weight 
marker. Amplificates were hybridized to a radiolabelled AccI-Hind111 
subfragment of the human AT, receptor cDNA as a probe. Methods 
are detailed in section 2. 
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Fig. 2. Secretion of TNFa by human peripheral blood monocytes. 
Dose-dependent stimulation of monocytes by either (A) LPS or (B) 
angiotensin II either alone (open symbols) or after preincubation with 
10 nM ZD 7155 (hlled symbols). LPS- and Ang II-induced TNFa 
secretion responses of monocytes from three separate donors are pre- 
sented (1 = o, 2 = A, 3 = q ). ZD 7155 completely inhibited Ang II- 
induced TNFa secretion in monocytes from the three different donors 
(o = 1,2 and 3). Data points represent mean values (S.D. < 10%) from 
triplicate measurements. All methods are detailed in section 2. 
confirmed by Southern Blot analysis (Fig. 1) and partial 
sequencing of the amplification products (not shown). 
The activation of blood moncytes by Ang II or LPS 
(as the positive reference) was monitored by measuring 
the release of TNF dl into culture supematant. LPS dose- 
dependently induced release of TNF a from monocytes 
(Fig. 2A). The maximal amounts of TNF a released 
varied between monocyte preparations from different 
donors (Fig. 2A). Ang II also induced secretion of TNF 
cc from blood monocytes (Fig. 2B). This response was 
dose-dependent (half-maximally effective concentration 
of = 0.2 nM) and saturable (maximally effective concen- 
tration = 1 nM), and as in the case of LPS-induced mon- 
ocyte activation, monocytes from different donors exhib- 
ited different maximal activation responses to Ang II 
(Fig. 2B). Ang II-induced release of TNF dl was com- 
pletely inhibited in monocytes preincubated with the AT, 
receptor antagonist, ZD 7155 (10 nM) (Fig. 2B). 
Compared to resting monocytes (~10% adhesion), 
Ang II-activated monocytes exhibited high adhesion 
(~70%) to monolayers of HUVEC (Fig. 3). In mon- 
ocytes preincubated with the AT1 receptor antagonist 
before Ang II treatment, adherence was not significantly 
different from controls (Fig. 3). 
4. Disc~ion 
‘Endothelial injury’ may be initiated by rheological 
parameters, and low shear stress has been demonstrated 
to be greatly conducive toward leucocyte adhesion to 
endothelial cells [3,9]. However, adherent/subendothelial 
monocytes in capacitance arteries of the spontaneously 
hypertensive rat exhibit a heterogenous regional distri- 
bution, namely present in the aorta and carotid artery 
but absent in the renal artery [6]. Furthermore, although 
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Fig. 3. Adhesion of human monocytes to human umbilical vein endo- 
thelial cells. Monocytes were incubated for 6 h in the presence of either 
5% human serum albumin (control) or Ang II (lo-8 M) with or without 
a 30 mm preincubation with ZD 7155 (lo-* M), and then tested for 
adhesion to HUVEC. All protocols are described in section 2. Results 
(mean f SD. from triplicate experiments) on monocytes from two do- 
nors (2 and 3 as in Fig. 2) are presented. 
both ACE1 and hydralazine lower blood pressure, only 
ACE1 effectively reduces monocyte macrophage intitra- 
tion and endothelial dysfunction [6,10]. It was thus pro- 
posed that the trigger of monocyte/macrophage adhesion 
stems rather from the vessel wall itself than from mere 
rheological parameters [6]. Our present report of Ang 
II-mediated activation of peripheral blood mononuclear 
cells and increased adhesion of Ang II-activated mon- 
ocytes to human endothelial cells is in support of such 
a proposal. 
We have demonstrated that Ang II is capable of acti- 
vating peripheral blood monocytes in a manner that is 
dose-dependent, saturable and sensitive to inhibition by 
ATi receptor antagonism. These observations, together 
with the expression of AT, receptor transcripts by mon- 
ocytes, suggests that Ang II-induced activation of mon- 
ocytes occurs via a receptor-mediated mechanism. The 
TNFa secretion response of monocytes to Ang II oc- 
curred at physiologically relevant concentrations of 
Ang II ( 1O-‘o-1O-g M), and at maximum was quantita- 
tively comparable to endotoxin (LPS)-induced TNFa re- 
lease from monocytes. TNF& has been demonstrated to 
exert a direct toxic effect on cultured vascular endothelial 
cells [l 11, and thus in vivo, the activation of monocytes 
by Ang II may initiate and/or perpetuate a status of 
‘endothelial injury’. 
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In vivo the vascular entothelial cell itself is the major 
source of Ang II [12]. Under normal conditions, endo- 
thelium-derived Ang II is secreted towards the cell layers 
of the tunica media rather than the huninal side of the 
vessel, and this is reflected in minimal amounts of circu- 
lating Ang II [13]. However, with age and in hyperten- 
sion, there is clear evidence for not only an elevated 
activity of angiotensin generating systems [13], but also 
elevated levels of circulating Ang II and a loss of endo- 
thelial cell polarity [14]. The concomitant beneficial ef- 
fects of ACEI treatment on monocyte adhesionltransmi- 
gration and endothelial dysfunction in hypertension may 
therefore be explained by inhibition of Ang II generation 
by ACE1 and the resultant reduction of monocyte activa- 
tion by this peptide. Direct prevention of Ang II-medi- 
ated monocyte activation by AT, receptor antagonism 
may provide a valuable therapeutic avenue for preven- 
tion of ‘endothelial activation/injury’ in both athero- 
sclerosis and hypertension. 
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